iMLGAM

iMLGAM predicts immunotherapy response by integrating machine learning and genetic algorithm approaches to establish a scoring system for multi-omics data analysis.

Key Features:

• Multi-omics integration: Integrates advanced multi-omics data to generate comprehensive scoring for treatment outcome prediction.
• Machine learning and genetic algorithm integration: Combines machine learning with genetic algorithm-driven optimization for predictive modeling.
• Pan-cancer applicability: Generates scores with predictive performance validated across independent cohorts in a pan-cancer context.
• Immune microenvironment characterization: Identifies distinctive tumor immune microenvironment features associated with score levels, including immune cell infiltration and antitumor immune response patterns.
• Therapeutic target identification: Enables discovery of molecules modulating tumor immune evasion, such as Centrosomal Protein 55 (CEP55).

Scientific Applications:

• Immune checkpoint blockade response prediction: Predicts treatment outcomes for immune checkpoint blockade therapy across cancer types.
• Biomarker development: Generates iMLGAM scores that outperform existing clinical biomarkers for predicting therapeutic response.
• Immune evasion mechanism elucidation: Identifies key regulators of tumor immune evasion and their mechanistic roles in T cell-mediated antitumor immunity.
• Therapeutic target prioritization: Discovers and validates promising therapeutic targets such as CEP55 to enhance immunotherapy efficacy.

Methodology:

iMLGAM integrates machine learning and genetic algorithm approaches with multi-omics data; clustered regularly interspaced short palindromic repeats screening was used to identify CEP55 as a key molecule modulating tumor immune evasion.